ArticleThe pharmacogenomics journal2013
Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction.
Article in The pharmacogenomics journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.The pharmacogenomics journal · 2018Trial
- Differential effect of beetroot bread on postprandial DBP according to Glu298Asp polymorphism in the eNOS gene: a pilot study.Journal of human hypertension · 2014Trial
- eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril.European journal of clinical pharmacology · 2013Trial
- Genetic biomarkers associated with risk and therapeutic response in erectile dysfunction: a systematic review.Frontiers in pharmacology · 2026Review
- The rs2682826 Polymorphism of theLife (Basel, Switzerland) · 2023Article
- Aqueous extract ofFood science and biotechnology · 2019Article
- Influence of arginase polymorphisms and arginase levels/activity on the response to erectile dysfunction therapy with sildenafil.The pharmacogenomics journal · 2018Article
- Network analysis of coronary artery disease risk genes elucidates disease mechanisms and druggable targets.Scientific reports · 2018Article
- Endothelial nitric oxide synthase: From biochemistry and gene structure to clinical implications of NOS3 polymorphisms.Gene · 2016 · on this mapReview
- [Genetic aspects of erectile dysfunction].Der Urologe. Ausg. A · 2015Review
- Endothelial nitric oxide synthase polymorphisms and haplotypes in genetic epidemiology and pharmacogenetics: remarks regarding a lack of association on the risk of myocardial infarction.Molecular biology reports · 2014Article
- VEGF genetic polymorphisms affect the responsiveness to sildenafil in clinical and postoperative erectile dysfunction.The pharmacogenomics journal · 2013Article
- Low nitric oxide bioavailability is associated with better responses to sildenafil in patients with erectile dysfunction.Naunyn-Schmiedeberg's archives of pharmacology · 2013Article
- Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics.Future cardiology · 2013Review
- Pharmacogenetic Implications of eNOS Polymorphisms (In vivo (Athens, Greece)Review
- Preliminary study about the relationship between estimated training status and RAS polymorphisms on blood pressure and ACE activity in the elderly.Journal of the renin-angiotensin-aldosterone system : JRAASArticle
- Vascular homeostasis at high-altitude: role of genetic variants and transcription factors.Pulmonary circulationReview
- Second look at the potential use of ginseng berry extract for treating erectile dysfunction.International journal of impotence researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erectile dysfunction (ED) is usually treated with sildenafil. Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil. We studied 118 patients; 63 patients had ED secondary to radical prostatectomy (PED) and 55 had organic, clinical ED. eNOS genotypes for three eNOS polymorphisms (T(-786)C, rs2070744; a variable number of tandem repeats (VNTR) in intron 4; and Glu298Asp, rs1799983) were determined, and eNOS haplotypes were estimated using PHASE 2.1. The clinical responses to sildenafil were evaluated and the patients were classified as good responders (GR) or poor responders (PR) when their changes in five-item version of International Index for Erectile Function questionnaire were above or below the median value. The TC/CC genotypes and the C allele for the T(-786)C polymorphism were more common in GR, compared with PR patients with PED. However, the 4b4a/4a4a genotypes and the 4a allele for the VNTR polymorphism in intron 4 were more common in GR, compared with PR patients with clinical ED. The C-4a-Glu haplotype was more common in GR than in PR patients with PED. Conversely, the T-4b-Asp haplotype was less common in GR than in PR patients with PED. No other significant differences were found. Our findings show evidence that eNOS polymorphisms affect the responses of PED and clinical ED patients to sildenafil.
Indexed as
Identifiers
22064666What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.